Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), David P. Ryan(East Carolina University), Pankaj Bhargava(University of North Carolina at Chapel Hill), Charles S. Fuchs(University of Southern California), Kerry Horgan(Beth Israel Deaconess Medical Center), Keith Stuart(Brigham and Women's Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Donald P. Reitberg(Bristol-Myers Squibb (United States)), Jeffrey W. Clark(Massachusetts General Hospital), Alona Muzikansky(Johns Hopkins University), Peter C. Enzinger(Dana-Farber Cancer Institute), Jeffrey A. Meyerhardt(CancerCare)
Cited by 248
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k